Angus Sinclair

Angus Sinclair currently serves as the Chief Scientific Officer at LabGenius Therapeutics since May 2025, leading efforts in next-generation antibody discovery utilizing high-throughput experimentation and machine learning. Prior to this role, Angus held multiple positions at IGM Biosciences, Inc., including Executive Vice President of Research and Senior Vice President of Immuno-Oncology from February 2018 to May 2025. Angus's earlier experience includes serving as Senior Director at Northern Biologics and various roles at Amgen, including Scientific Director, where responsibilities involved managing preclinical hematology/oncology discovery programs and overseeing scientific teams in California and Massachusetts. Education includes a Ph.D. in Hematology/Molecular Biology from UCL and a B.Sc. in Molecular Biology from The University of Edinburgh.